key: cord-0015761-00s5jfs1
authors: Hsu, Hui-Ching; Chang, Yu-Sheng; Hou, Tsung-Yun; Chen, Lung-Fang; Hu, Li-Fang; Lin, Tzu-Min; Chiou, Chi-Sheng; Tsai, Kai-Len; Lin, Sheng-Hong; Kuo, Pei-I; Chen, Wei-Sheng; Lin, Yi-Chun; Chen, Jin-Hua; Chang, Chi-Ching
title: Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study
date: 2021-03-01
journal: Clin Rheumatol
DOI: 10.1007/s10067-021-05660-4
sha: ca108728b207f161174ac5dce8b99628686076f9
doc_id: 15761
cord_uid: 00s5jfs1

OBJECTIVE: To compare Pneumocystis jirovecii pneumonia (PJP) risk between patients with autoimmune rheumatic diseases (ARD) and the general population METHODS: We identified patients with ARD recorded in the National Health Insurance Research Database of Taiwan from 2002 to 2015 and randomly selected a comparison cohort from the general population matched for age and sex. We analyzed PJP risk stratified by sex, age, comorbidities, and medications using Cox proportional hazard model. RESULTS: We enrolled 103,117 patients with ARD. PJP risk significantly increased in patients with any ARD and with each individual ARD like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren’s syndrome (SjS), polymyositis and dermatomyositis (PM/DM), systemic sclerosis (SSc), and systemic vasculitis. Patients with PM/DM showed prominent risk with incidence rate of 12.47/100,000 patient year (95% confidence interval (CI), 32.16–86.70). In a time-dependent Cox proportional hazard model with comorbidities and medications as covariates, PM/DM, SSc, SLE, and SjS significantly increased adjusted hazard ratios (aHR) of 5.40, 5.12, 4.09, and 3.64, respectively (95% CI of 2.82–10.35, 2.16–12.13, 2.41–6.95, and 2.06–6.42, respectively). AHR after adjusting for male sex, cancer, human immunodeficiency virus infection (HIV), and interstitial lung disease also significantly increased. Use of daily oral steroid dose of >10 mg conferred the highest risk followed by mycophenolate. Use of injected steroids, cyclophosphamide, biological agents, methotrexate, and cyclosporine conferred a significantly higher risk. CONCLUSION: Underlying ARD significantly predisposes patients to PJP, with PM/DM posing the highest threat. In addition to underlying disease, comorbidities and concomitant immunosuppressants are major risks. The strongest risk is recent daily steroid dose of >10 mg. Mycophenolate seems to be a more prominent risk factor than cyclophosphamide.

Pneumocystis jirovecii is an opportunistic organism that can cause high mortality among immunosuppressed patients including those with human immunodeficiency virus infection (HIV), malignancy, and underlying autoimmune rheumatic diseases (ARD) [1, 2] . In recent years, due to the progress of organ transplantation, tumor chemotherapy, and ARD treatment, the number of non-HIV patients infected by Pneumocystis jirovecii has gradually increased [3] . Patients with underlying ARD may be exposed to immunosuppressive drugs, corticosteroid, biological agents, and cyclophosphamide, rendering them more vulnerable to Pneumocystis jirovecii pneumonia (PJP) [4, 5] . Mortality rates among non-HIV patients diagnosed with PJP are high (estimated to be between 39.4 and 59.1%), making this an important population to target for prophylaxis [6] . Trimethoprim/ sulfamethoxazole prophylaxis in patients with ARD can significantly reduce incidence of PJP [5, 7] . Therefore, identifying patients with ARD and a high risk of PJP is crucial for adequate initiation of Pneumocystis jirovecii prophylaxis, which may improve patient outcomes as has proven effective for HIV patients [8] .

In previous reports of ARD, the most common underlying condition for development of PJP is Wegener's granulomatosis (8-12%), followed by polyarteritis nodosa (PAN) (6.5%), polymyositis and dermatomyositis (PM/DM) (2.7%), systemic lupus erythematosus (SLE) (2%), and rheumatoid arthritis (RA) (0.1-0.3%) [9] . However, data on the prevalence of PJP in ARD is relatively limited. Several comorbidities other than HIV, malignancy, or ARD may also increase risks of PJP, such as renal transplantation [10, 11] , end-stage renal disease (ESRD) [11] , or interstitial lung disease (ILD) [12] , which adds to the complexity of risk evaluation and management.

In addition to the patient's underlying diseases, high-dose steroid use and immunosuppressants were found to increase the risk of PJP in patients with ARD [10, 13] . Patients with ARD receiving an initial steroid dose of ≥60 mg/day prednisolone equivalent were also found to have a higher risk for PJP [5] . Significant risk factors for PJP included higher age, male sex, underlying lung disease, use of corticosteroids, use of methotrexate, and use of biologics (anti-TNF alpha, anti-IL-6 receptor antibody, or anti-T-cell costimulatory pathway agents) in patients with RA [8, 14] . Anti-CD20 and cyclophosphamide use were also related to increased risk of PJP in patients with SLE or malignancy [15, 16] .

To summarize, the host's underlying disease and comorbidity, which directs different combination of immunosuppressant use including different dosage and duration, contribute greatly to the variability and complexity of PJP in clinical practice. Due to the rare occurrence but high mortality of PJP infection in patients with ARD, it is crucial to determine the risk of PJP infection individually when considering the initiation of prophylaxis. This study aims to determine (1) the risk of PJP with underlying ARD as a whole or individual ARD, (2) comorbidities that pose additional risks, and (3) effects of immunosuppressants, steroid, biologics, and cyclophosphamide on the risk of PJP. Using nationwide data on PJP in patients with ARD, we aimed to better understand this condition under complex clinical settings.

The National Health Insurance (NHI) program in Taiwan was instituted in 1995 to provide comprehensive health care for nearly all Taiwanese citizens and has a coverage rate of 99%. For research purposes, the bureau of NHI in Taiwan released the National Health Insurance Research Database (NHIRD), which provides detailed claim data for outpatient clinics, admission, and drug prescriptions of patients enrolled in the NHI. For this study, we collected data from the NHIRD from January 1, 2002, to December 31, 2015. Since the data sets used in this study were comprised of de-identified secondary data for research purposes, patient consent was not required for this study. This study was approved by the Taipei Medical University institutional review board (approval numbers N201509007 and N201908055). The diagnostic codes used in this data set were based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

We conducted a retrospective matched cohort study using the NHIRD of Taiwan to investigate the risk of PJP of patients with and without ARD (Fig. 1) . The NHIRD established a registry system for catastrophic illnesses. In Taiwan, after a rheumatologist makes a diagnosis based on a patient's clinical features and laboratory and image results, patients who [25] , and giant cell arteritis (ICD-9-CM: 446.5) [26] .

Patients with their first new catastrophic illness registration of each ARD between 2002 and 2015 were enrolled, including those with RA, SLE, SjS, PM/DM, SSc, and systemic vasculitis (SV). The SV group comprised patients with PAN, hypersensitivity angiitis, Wegener's granulomatosis, giant cell arteritis, and Buerger's disease. The primary endpoint was incidence of PJP infection defined as pneumocystosis (ICD-9-CM: 136.3) in the discharge diagnosis. Patients with unknown sex or age or with PJP prior to enrollment were excluded. Patients with overlapping ARDs were excluded. Each patient with ARD was matched with four non-ARD subjects for age and sex based on the same exclusion criteria. All patients were followed until the development of primary endpoint, end of the study period, or discontinuance of insurance.

For continuous variables, we employed Student's t tests to evaluate the differences between the case group and the comparison group, and for categorical variables in our baseline analysis, we evaluated differences between the two groups using Pearson's chi-squared tests. An incidence rate ratio (IRR) was constructed to compare the incidence between the groups, and the confidence interval (CI) of IRR was calculated using normal approximation. The cumulative incidence rate and Gray's test for equality of cumulative incidence functions were employed to compare the risk of PJP infection between the two cohorts.

A Cox proportional hazard model was applied to evaluate the factors associated with PJP infection. Factors analyzed in the model included age, sex, type of ARD, comorbidities, and medications leading to immunosuppression status. Comorbidities within 1 year before the index date that may lead to immunosuppression were identified using the corresponding ICD-9-CM, including cancer, HIV, renal transplant, ESRD, ILD, congestive heart failure, diabetes mellitus, hypertension, cirrhosis, and stroke. Medications used during the study period were analyzed as time-dependent covariates, such as hydroxychloroquine, methotrexate, mycophenolate, azathioprine, cyclosporine, cyclophosphamide, steroid, and biologics. Biologics consisted of etanercept, adalimumab, golimumab, rituximab, tocilizumab, and abatacept. The follow-up period of each patient was retrospectively divided into successive 120-day blocks; the prescription status of each medication in each 120-day block and its association with the occurrence of the event at the end of each time block were analyzed. Oral steroid use was analyzed according to the average daily dose in the time block, with a cutoff point of 5 and 10 mg prednisolone equivalent. All factors with p < 0.1 in the univariate analysis were selected for Cox multivariate forward stepwise analysis. The results of all statistical tests were considered significant if p < 0.05.

There were 103,117 patients with ARD and 412,468 matched controls enrolled in this study ( Table 1 ). The majority of patients in both cohorts were female (81.58%) and the mean age was 50.4 years in both groups. The ARD group had significantly increased comorbidities and medication use. The detailed use of each medication is shown in Supplementary Material Table 1 .

The ARD group had a significantly higher incidence of PJP development than the comparison group during the observation period (0.18% vs. 0.01%, p < 0.0001) ( Table 1 ). The incidence rates (IR) and IRR of PJP during the follow-up period revealed a significantly higher risk in patients with each individual ARD ( Table 2 . The incidence rate analyses for individual ARD and overall ARD also revealed a significantly higher risk of PJP infection (Fig. 2,  Supplementary Material Figure 1 ).

To analyze risk factors associated with PJP infection, a multivariate Cox proportional hazard analysis was applied to all study participants (Table 3) . Age, male sex, and comorbidities including malignancy, HIV, and ILD significantly increased the risk of PJP. After adjusting for sex, age, and comorbidities, several medications analyzed as time-dependent covariates in the model significantly related to PJP infection. The medication with the highest risk was daily oral steroid dose of >10 mg prednisolone equivalent (aHR 9.15, 95% CI 6.23-13.45), followed by (in order of risk) mycophenolate (aHR 7.14, 95% CI 4. 

Previous studies of PJP in autoimmune diseases are mostly case series and single-center experiences of one or a few ARD, with a relatively low incidence of PJP. To the best of our knowledge, this is the first study to attempt a broad, population-based perspective to better understand PJP in patients with ARD, especially in patients with SSc and SjS. Patients with ARD had a significantly higher risk of PJP. In our multivariate Cox proportional hazard analysis, patients with PM/DM had the highest risk, followed by those with SSc, SLE, and SjS. The factors associated with PJP included comorbidity-related secondary immunosuppression and immunosuppressant use such as steroid, mycophenolate, biologic agents, cyclophosphamide, methotrexate, and cyclosporine.

Patients with different ARD were at differing risks of PJP. In previous studies of PJP, the most common ARD were inflammatory myopathy, SLE, ANCA-associated vasculitis, and RA [3, 27, 28] . SSc and SjS have not been previously reported to be associated with higher risk of PJP infection, but in this study, patients with SSc or SjS had a significantly higher risk of PJP, and the risk in patients with SSc was even higher than that in patients with SLE. In addition, the ARD with the highest PJP risk was neither SLE nor SV; patients with PM/DM had the highest risk followed by SV and SSc. In our multivariate Cox proportional hazard analysis, most ARD still had a risk of PJP after adjusting for all related factors. This was not true for RA or SV, which means the increased risk of PJP in patients with RA and SV may come mostly from the immunosuppressants and related comorbidities such as ILD; therefore, the risk was no longer significant after adjusting for these factors. However, we believe that there were other reasons that lead to our failure to demonstrate the significant risk in patients with SV. The wide 95% CI implied that the patient year of SV was too low to have sufficient statistical power to show significance and only a trend toward higher risk remained in the model. The relatively lower patient year in the SV cohort might be due to the low prevalence and high mortality rate of this disease.

Among immunosuppressants, the risk of cyclophosphamide is well-documented and related prophylactic strategies were established in patients with hematological malignancies [29] . Of note, several medications had higher risk than cyclophosphamide in this study. The highest was daily oral steroid use over 10 mg prednisolone equivalent. Injected steroid therapy also had an increased risk. This result is consistent with previous reports emphasizing the risk of opportunistic infections such as Pneumocystis jirovecii in patients with high-dose steroid use, and this effect seems to be dose-dependent, regardless of underlying disease [5, 30, 31] . Cumulative steroid dose, duration of steroid use, and daily steroid dose all had prominent impacts on the risk of infection. It was demonstrated that current and recent doses of steroid have the greatest impact on infection risk, but the cumulative impact of doses taken in the past few years still affects risk in patients with RA [32] . Use of steroids, mycophenolate, biological agents, cyclophosphamide, methotrexate, and cyclosporine had significantly increased risks of PJP infection. It is noteworthy that mycophenolate is believed to be equally effective but better tolerated than cyclophosphamide, but in our model, the risk of PJP with mycophenolate was even higher than that with cyclophosphamide. There has been a single-center report of increased mortality of PJP in patients with ARD receiving mycophenolate [33] . Moreover, in Taiwan, biological agents endorsed by NHI were mostly used for treating RA. There have been reports of PJP infection in patients with RA under etanercept, adalimumab, golimumab, rituximab, tocilizumab, or abatacept treatment [8, 14, 34] . Our results also showed a significantly higher risk of PJP infection in patients using biological agents. Due to the paucity of evidence regarding primary prophylaxis of PJP in ARD, the initiation of prophylaxis in patients with ARD is still based on expert opinion with no clear recommendations [35] . The initiation and duration of trimethoprim/sulfamethoxazole prophylaxis should be considered in high risk patients in a patient-based manner [35] . This study provided data on the individual risk of each immunosuppressant, which may add insight to evaluating the overall risk of PJP under different clinical settings and assist decision-making on prophylaxis of this serious disease. Several basic characteristics were associated with PJP risk. Similar to a previous report in RA, older age and male sex were related to a higher risk of PJP [14] . Our study showed that underlying ARD, malignancy, HIV, and ILD contribute to PJP infection. ILD was associated with increased pulmonary colonization by Pneumocystis jirovecii, which may explain this increased risk [12] .

Our study had several strengths including the long followup and the use of population-based, nationwide cohorts and the large study sample that may increase statistical precision. In addition, we validated ARD diagnosis by catastrophic illness registration. In the NHI system, patients with the catastrophic illness registration for ARD can be exempted from related medical expense. However, the verification requires fulfillment of the classification criteria of each ARD, as supported by medical records and examination reports. These features made the ARD diagnosis more reliable. Second, we analyzed immunosuppressants as time-dependent variables in a multivariate Cox-regression model, which could fit in with the temporal relationship between medication and the subsequent increased risk of PJP infection.

Our study had several limitations. First, because the NHI database does not include clinical data or culture results, we could not analyze information such as patients' lymphocyte count, CD4 count, or serum LDH level, which might have an additional predictive value of PJP [6, 36] . However, the main goal of this study was to investigate the epidemiology of PJP in ARD, especially ARD that have been less studied in this context such as PM/DM, SSc, and SjS and the risk of individual medications. Second, different biologics were analyzed together despite the fact that different biologics might have different risks of PJP infection. We decided to simplify the analysis by combining different biologics as one variable because there were too many variables in the model given the low incidence of PJP events and the biologics were mainly used in patients with RA. We will focus on this issue in patients with RA in the future. The situation was similar in SV; we included different types of vasculitis as a single cohort due to relatively low case numbers of each type of vasculitis. However, we believe that the risk differed with different types of vasculitis.

This study revealed the increased risk and epidemiologic data of PJP infection in several ARD including ARD with few reports on, such as SSc and SjS. The risk was highest in patients with PM/DM followed by SV, SSc, SLE, SjS, and RA. This study also included risk factors for PJP infection such as male gender, older age, and comorbidities like cancer, HIV, or ILD, or immunosuppressants including steroid, mycophenolate, cyclophosphamide, biologics, methotrexate, and cyclosporine. These data provide fundamental insights for further studies on prophylactic antibiotics for PJP for these populations.

Author contributions All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Hui-Ching Hsu and Yu-Sheng Chang contributed to study conception and design, article drafting, data interpretation, critical article revision for crucial intellectual content, and the final approval of the submitted version. Tsung-Yun Hou, Lung-Fang Chen, Li-Fang Hu, Tzu-Min Lin, Chi-Sheng Chiou, Kai-Len Tsai, Sheng-Hong Lin, Pei-I Kuo, Wei-Sheng Chen, and Yi-Chun Lin contributed to data analysis, critical article revision for crucial intellectual content, and the final approval of the submitted version. Jin-Hua Chen and Chi-Ching Chang were responsible for study conception and design, complete data analysis, critical article revision for crucial intellectual content, and correspondence regarding the final approval of the submitted version.

The manuscript does not contain clinical studies or patient data.

Disclosures None.

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy

Pneumocystis jirovecci pneumonia in connective tissue diseases: comparison with other immunocompromised patients

Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients

Use of glucocorticoids and risk of infections

Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids

Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: a case-control study

Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIVinfected patients: systematic review and meta-analysis of randomized controlled trials

Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients: risks and prophylaxis recommendations

Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients

Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis

Pneumocystis jirovecii pneumonia in patients with end-stage renal disease: a comparison with the general population

Pneumocystis jirovecii colonisation in patients with interstitial lung disease

A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole

Incidence and risk factors for infections requiring hospitalization, including Pneumocystis pneumonia

Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy

Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for classification of systemic sclerosis (scleroderma)

Polymyositis and dermatomyositis (First of two parts)

Polymyositis and dermatomyositis (Second of two parts)

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

Thromboangiitis obliterans

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis

The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis

Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis

Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience

ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Infection risk and safety of corticosteroid use

Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question

Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis

Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases

Comparison of the Clinical characteristics of Pneumocystis pneumonia between patients with rheumatoid arthritis being treated with biologics and those being treated without biologics

Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases

Pneumocystis carinii pneumonia in patients with connective tissue disease

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations